The chemotherapy-sensitizing effects of direct GHR antagonism in preclinical models of human melanoma, breast cancer, and liver cancer exhibit a consistent suppression of ABC multidrug transporters and markers of EMT, leading us to hypothesize that targeting GHR in PDAC can reverse the chemoresistant phenotype of this cancer. This evidence concerns the gene GHR and liver cancer.